NCT04370834 2025-02-04
Tocilizumab for Patients With Cancer and COVID-19 Disease
National Cancer Institute (NCI)
Phase 2 Terminated
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
University of Michigan Rogel Cancer Center